---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000039"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:33:10.585923+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ligand completes $75M purchase of Agenus royalty rights

## Summary
- Completed purchase of royalty rights from Agenus Inc. for $75M on May 29, 2024.
- Transaction previously announced on May 7, 2024; customary closing conditions satisfied.
- No other terms or financial impact disclosed beyond the purchase price.

## SEC filing metadata
- accession: 0000886163-24-000039
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000039/0000886163-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000039/lgnd-20240529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000039
- JSON: https://secwatch.observer/filing/0000886163-24-000039.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.